Precision Therapy in Lung Cancer: FAQ on Biomarkers for Immune Checkpoint Inhibitors

In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on current and evolving biomarkers for immune checkpoint inhibitor–based therapies in advanced non-small-cell lung cancer with topics including:

• Selecting therapy for advanced NSCLC without actionable mutations and with different levels of PD-L1 expression
• Choosing therapy for advanced NSCLC with an actionable mutation on NGS and high PD-L1 expression
• Leveraging key data from CheckMate 9LA to identify patients who may benefit from chemotherapy plus nivolumab/ipilimumab
• STK11/KEAP1 as potential predictors for a lack of response to immune checkpoint inhibitor–based therapy
• Treatment for NSCLC after progression on chemotherapy plus an immune checkpoint inhibitor
• Rechallenging after stopping immune checkpoint inhibitor due to immune-related adverse events

Presenters:

Edward S. Kim, MD, FACP
Chair, Solid Tumor Oncology and Investigational Therapeutics
Donald S. Kim Distinguished Chair for Cancer Research
Levine Cancer Institute
Atrium Health
Charlotte, North Carolina

Leora Horn, MD, MSc, FRCPC
Ingram Associate Professor of Cancer Research
Director, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt Ingram Cancer Center
Nashville, Tennessee

Content based on an online CME program supported by an educational grant from Lilly.

Link to full program, including associated downloadable slidesets: https://bit.ly/3a3e1Xs

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.